The FDA 510(k) database entry for K254119 lists Shenzhen Xinyan Medical Technology Co.,ltd. as applicant for eight device names spanning two model families: Wearable ECG Recorder (YMHeart XY-12), XY-1201, XY-1202, XY-1203, and Wearable ECG Recorder (YMHeart XY-03), XY-0301, XY-0302, XY-0303. The submission was received on 2025-12-19 and decided on 2026-09-11 with decision code SESE, described as Substantially Equivalent, under a Traditional clearance type with a Summary statement. The regulation number is 870.2800 and the classification name is Electrocardiograph, Ambulatory (Without Analysis), placing the devices in class 2 with a cardiovascular advisory committee. [1][7][8]
The applicant and the cleared device family
The applicant name appears consistently across the FDA export, the agency's 510(k) database page and third-party indexes of the same record. The device names are long-form listings that enumerate each model variant, so the clearance covers a set of eight named configurations rather than a single model. The product code MWJ and regulation 870.2800 identify the regulatory category as an ambulatory electrocardiograph without analysis, and the review panel is recorded as cardiovascular. [1][7][9]
A third-party registry record for K254119 restates the same decision, date and product code, and notes that the agency record at api.fda.gov governs where the two differ. The FDA.report index likewise lists the applicant, product code, decision, decision date, date received, regulation and classification name in agreement with the agency export. [8][7]
Submission dates and review pathway
The filing timeline is documented: date received 2025-12-19, decision date 2026-09-11, decision code SESE, decision description Substantially Equivalent, clearance type Traditional, third-party flag N, and statement or summary marked Summary. The advisory committee and review advisory committee are both recorded as CV, with the description Cardiovascular. The agency's database page carries a page update date of 11/02/2026. [1][2]
The FDA decision letter addressed to the applicant, care of a named consultant in Guangzhou, is dated September 11, 2026 and references K254119 with the same trade/device names. The letter's comparison table lists the applicant's proprietary name alongside other named devices and manufacturers, which is the standard format for a substantial-equivalence review rather than an indication of shared ownership. [3]
Product descriptions published by the company
Company product pages describe two configurations. The 3-lead page lists models YMHeart XY-03 and XY-0301 through XY-0303 with ECG Sensor-030 through 039, 3-lead synchronous collection, 7-14 days of continuous monitoring, Bluetooth plus USB upload, and a stated report accuracy of 98.8%. The 12-lead page lists models YMHeart XY-12 and XY-1201 through XY-1203 with ECG Sensor-120 through 134, 12-lead synchronization, cloud-based data synchronization and multimodal reports, positioned for hospital, emergency and remote-consultation use. These are the company's own published descriptions. [4][6]
A company announcement states that the series received both NMPA and FDA clearance, citing K254119 and the September 11, 2026 date, and describes planned expansion toward Europe, Southeast Asia and the Middle East. The announcement is the publisher's characterization of its own regulatory status and market intentions. [5]
What the supplied filings do and do not establish
The supplied collection contains one linked 510(k) record, K254119, with a decision count of one SESE in both the full collection and the single-record sample. That count describes the supplied filings as of the snapshot; it is not a measure of total company sales, total portfolio or safety performance. No recall records appear in the supplied sample. The FDA filing address in Shenzhen is a correspondence address on the submission and is not treated here as a verified headquarters. No parent, brand owner or corporate affiliate is verified in the sources. [1][8][9]
